Pranlukast

Pranlukast

File:Pranlukast.svg
Systematic (IUPAC) name
N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-chromen-7-yl]-4-(4-phenylbutoxy)benzamide
Clinical data
Routes of administration	Oral
Pharmacokinetic data
Metabolism	Hepatic (mainly CYP3A4)
Biological half-life	1.5 hours
Identifiers
ATC code	R03DC02 (WHO)
PubChem	CID 115100
Chemical data
Formula	C27H23N5O4
Molar mass	481.503 g/mol[[]]

Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. This drug works similarly to Merck & Co.'s Singulair (montelukast). It is currently under clinical trials.

Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. There are several similar medications in the group; all appear to be equally effective.